BriaCell Therapeutics Corp. marked 71% intracranial objective response rate (iORR) in advanced breast cancer patients suffering from central nervous system (CNS) metastases and treated with BriaCell?s Bria-IMT? regimen.

iORR is defined as the percentage of patients who achieve either a complete response (complete disappearance) or partial response (volume reduction of 30% or more) in intracranial tumors. Breast cancer metastasis (spread of the cancer) to the CNS presents a significant clinical challenge, often leading to poor prognosis and early death. BriaCell has recently conducted a retrospective analysis in breast cancer patients with CNS metastases enrolled across both its Bria-IMT?

monotherapy and combination therapy with CPI studies and found remarkable clinical responses. BriaCell Clinical Data in Advanced Metastatic Breast Cancer Patients with CNS Metastases. The Bria-IMT?

Regimen (Alone or Combined with a CPI): CNS lesions improved in 71% of patients (5 of 7), supporting clinical efficacy of the Bria-IMT? regimen Findings provide evidence for the efficacy of the Bria-IMT? regimen, both alone and in combination with CPI, in CNS metastases patients Heavily pretreated metastatic breast cancer patients had failed multiple prior treatments including one patient who had failed treatments with 2 antibody-drug conjugates Regression of CNS metastatic tumors was observed across all breast cancer subtypes in heavily pretreated patients highlighting the potential of the Bria-IMT?

regimen in managing CNS metastases BriaCell is adding a pre-planned subgroup analysis of patients with CNS metastases to its pivotal Phase 3 study in advanced metastatic breast cancer patients. This could provide an additional indication for market approval of Bria-IMT?.